Skip to main content

Table 3 Overall response rates (ORR) and disease control rates (DCR) (n = 70 patients totally)

From: Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma

Patients with measurable disease (and at least one tumor assessment)

Cutaneous melanoma

Mucosal melanoma

Melanoma of unknown primary

N

%

N

%

N

%

No. patients  (%)

55

100

6

100

9

100

Response pattern (acc. to RECIST)

Complete response

 

 

 

Partial response

9

16

1

17

1

11

Stable disease

7

13

2

33

1

11

Progressive disease

39

71

3

50

7

78

Best ORR (according to RECIST)

ORR (=CR + PR)

9

16

1

17

1

11

ORR at week 12

7

13

1

17

 

ORR at week 24

6

11

1

17

 

Best DCR (according to RECIST)

DCR (=CR + PR + SD)

16

29

3

50

2

22

DCR at week 12

15

27

3

50

2

22

DCR at week 24

10

18

1

17

1

11

  1. CR complete response, PR partial response, RECIST response evaluation criteria in solid tumors, SD stable disease